• Iba – Acquisition of Own Shares - 20210903

    Source: Nasdaq GlobeNewswire / 03 Sep 2021 11:00:00   America/Chicago

    Immediate Release – September 3rd, 2021

    Louvain-la-Neuve, Belgium, September 3rd, 2021 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on June 29th, 2021.

    Under this program, IBA has requested a financial intermediary to repurchase up to 250.000 IBA ordinary shares on its behalf under the terms of a discretionary mandate agreement with validity until December 30th, 2021, effective as from June 30th, 2021, to cover the company’s obligations under a long term incentive plan for certain members of its personnel.

    In the framework of this share buyback program, IBA repurchased 5.057 IBA shares on Euronext Brussels in the period from August 27th, 2021 up to and including September 2nd, 2021, as follows:

    Trade dateShares purchasedAverage priceMin priceMax priceBuyback amount
    27-08-211.28917,08 €16,98 €17,30 €22.011,22 €
    30-08-2165117,00 €17,00 €17,00 €11.067,00 €
    31-08-212.55816,88 €16,80 €17,00 €43.179,81 €
    01-09-2120916,99 €16,82 €17,20 €3.551,52 €
    02-09-2135017,70 €17,70 €17,70 €6.195,00 €
    TOTAL5.05717,01 €16,80 €17,70 €86.004,55 €

    The total number of shares purchased under this program therefore amounts to 171.000. As a result, the current situation with respect to treasury shares (held directly by IBA SA and indirectly through its subsidiary IBA Investments SCRL) is the following:

      SharesVoting rights
    IBA Investments SCRL51.97351.973
    IBA SA 534.008597.377
    Total - Treasury shares585.981649.350
    Total - Issued shares30.133.92038.254.747
    Treasury shares in %1,94%1,70%


    About IBA

    IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,500 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

    IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

    More information can be found at: www.iba-worldwide.com

    CONTACTS
    Christian Matton,
    IBA Chief Legal Officer
    shareholderrelations@iba-group.com

    Attachment


Share on,